Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5281022 | 0.82 | CTBP2 (0.48) | RIPK1KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL5792784 | 0.80 | MAPT (0.49) | MAPTMAPK1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL18473845 | 0.78 | MMP8 (0.56) | MAPTMAPK1RIPK1KMT2ASMN1; SMN2 | |
| SCHEMBL7059318 | 0.78 | PLAAT3 (0.52) | MAPTMAPK1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL7643117 | 0.77 | PLAAT3 (0.53) | MAPTMAPK1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL24019666 | 0.76 | RIPK1 (0.45) | MAPTMAPK1RIPK1KMT2ASMN1; SMN2 | |
| SCHEMBL29277184 | 0.75 | MAPT (0.47) | MAPTMAPK1RIPK1KMT2ASMN1; SMN2 | |
| SCHEMBL24112710 | 0.75 | MAOB (0.45) | RIPK1ALDH1A1HPGDKDM4EMAOB | |
| SCHEMBL2596957 | 0.75 | MAPT (0.47) | MAPTMAPK1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL22877743 | 0.75 | PNMT (0.47) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146773-A | 6, 7, 8, 9-tetrahydro-5-amino-5h-benzocyclohepten-6-ol derivatives and related compounds used as anti-inflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863765-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| WO-2006100099-A1 | 6, 7, 8, 9-TETRAHYDRO-5-AMINO-5H-BENZOCYCLOHEPTEN-6-OL DERIVATIVES AND RELATED COMPOUNDS USED AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247292-A1 | Benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents | TNF, NFKBIA, PTGES | MAPT 2268/4885MAPK1 1524/4885GAA 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.